New treatment strategies for aggressive prostate cancer
Novel Radioimmunotherapy Strategies for Prostate Cancer
This study is looking for new ways to treat aggressive variant prostate cancer, which is a tough type of prostate cancer that doesn't respond well to regular treatments, by finding special markers on the cancer cells and creating targeted therapies that could help patients who have few options left.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10650786 on NIH RePORTER |
What this research studies
This research focuses on developing innovative radioimmunotherapy approaches specifically for aggressive variant prostate cancer (AVPC), a lethal form of prostate cancer that does not respond to standard treatments. The team aims to identify unique cell-surface antigens specific to AVPC and create targeted therapies using novel antibody constructs. Additionally, they will explore the use of small-molecule drugs to enhance the effectiveness of these therapies. By utilizing advanced techniques, the research seeks to provide new options for patients who currently have limited treatment alternatives.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with aggressive variant prostate cancer who have not responded to second-generation anti-androgen therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone anti-androgen therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective new treatment options for patients with aggressive variant prostate cancer.
How similar studies have performed: While radioimmunotherapy has shown promise in treating other forms of prostate cancer, this specific approach targeting AVPC is novel and has not been extensively tested.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Lebeau, Aaron Matthew — University of Wisconsin-Madison
- Study coordinator: Lebeau, Aaron Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.